Yttrium-90 Radioembolization: A Comprehensive Clinical and Radiopharmaceutical Review

Section 1: Yttrium-90: Isotopic Properties and Therapeutic Rationale

Yttrium-90 (Y-90), a radioactive isotope of the element yttrium, has emerged as a cornerstone in the field of interventional oncology, particularly for the treatment of hepatic malignancies. Its therapeutic efficacy is rooted in a unique combination of radiochemical properties and a sophisticated, targeted delivery mechanism. This section details the fundamental characteristics of the Y-90 isotope and the biological rationale underpinning its use in the advanced radiotherapeutic procedure known as transarterial radioembolization (TARE), or selective internal radiation therapy (SIRT).

1.1 Radiochemical Profile of Yttrium-90

The suitability of Yttrium-90 for locoregional cancer therapy is not coincidental; its physical properties are exceptionally well-matched for delivering a potent, localized, and temporally contained radiation dose. It is a pure beta (${\beta}^{-}$) particle emitter, a critical characteristic that defines its therapeutic action.[1] During its decay process, Y-90 transforms into the stable, non-radioactive isotope Zirconium-90 ($^{90}$Zr).[1] This decay is characterized by the emission of high-energy electrons with a maximum energy of 2.28 MeV and a potent average energy of approximately 0.93 MeV.[1]

The particulate nature of this beta radiation results in a very limited penetration range within biological tissues. The mean path length is approximately 2.5 mm, with a maximum reach of 11 mm.[1] This short range, equivalent to about 1,000 cell diameters, is profoundly advantageous. It allows for the deposition of a highly cytotoxic radiation dose directly within a tumor while significantly sparing adjacent healthy liver parenchyma and surrounding organs from collateral damage.[1] Although Y-90 is not a gamma emitter, its presence and distribution within the liver can be visualized post-procedure. This is achieved by detecting the secondary Bremsstrahlung X-rays, which are produced as the high-energy beta particles decelerate within the tissue. This phenomenon enables confirmation of microsphere placement using imaging modalities like single-photon emission computed tomography (SPECT/CT).[2]

The temporal profile of Y-90's radiation delivery is governed by its physical half-life of 64.1 hours (approximately 2.67 days).[1] This duration is long enough to permit complex manufacturing, calibration, shipping, and administration processes without significant loss of potency. At the same time, it is short enough to ensure that the majority of the therapeutic dose (94%) is delivered within a clinically relevant timeframe of 11 days, after which the radioactivity in the patient's body diminishes rapidly.[4]

Production of medical-grade Y-90 is accomplished through two distinct pathways, each with unique logistical and safety considerations. The first method involves the nuclear decay of Strontium-90 ($^{90}$Sr), a long-lived fission product (half-life of ~29 years) generated in nuclear reactors.[2] In this process, the Y-90 daughter product is chemically separated, or "milked," from the $^{90}$Sr parent source.[2] This method requires exceptionally stringent purification protocols, as any residual $^{90}$Sr contamination poses a significant health risk; its chemical similarity to calcium leads to its accumulation in bone, with potentially severe biological consequences.[14] The second production method is the direct neutron activation of stable, naturally occurring Yttrium-89 ($^{89}$Y) targets within a nuclear research reactor.[2] This route avoids the issue of $^{90}$Sr contamination entirely but is dependent on access to reactor facilities.

1.2 The Principle of Transarterial Radioembolization (TARE/SIRT)

TARE, also known as SIRT, is a sophisticated, minimally invasive procedure that leverages the physical properties of Y-90 to function as a powerful form of internal radiation therapy, or brachytherapy.[8] The procedure's success is predicated on a deep understanding of hepatic vascular anatomy and tumor biology.

The primary mechanism of action is the induction of cell death through high-dose radiation.[1] The beta particles emitted by Y-90 inflict lethal, irreparable damage to cellular DNA, both through direct ionization of molecular bonds and through the indirect generation of highly reactive free radicals from water molecules within the cells.[7] This damage overwhelms the cancer cells' repair mechanisms, triggering apoptosis (programmed cell death) and leading to tumor necrosis.[7] While radiation is the dominant therapeutic force, the procedure also imparts a secondary embolic effect. The physical lodging of millions of microspheres within the tumor's microvasculature obstructs blood flow, contributing to ischemic injury by depriving the tumor of essential oxygen and nutrients.[18] The degree to which embolization contributes to the overall therapeutic outcome is dependent on the specific type and number of microspheres administered, a key differentiator between commercially available products.

The targeted nature of TARE is made possible by the unique dual blood supply of the liver. Normal, healthy liver parenchyma derives the majority of its blood supply (~75%) from the low-pressure portal venous system, with only a minor contribution (~25%) from the hepatic artery.[1] In stark contrast, primary and metastatic liver tumors are hypervascular, deriving 80-90% or more of their blood supply from the high-pressure hepatic arterial system.[1] By selectively delivering Y-90-loaded microspheres into the hepatic artery via an intra-arterial catheter, the particles are preferentially streamed into the tumor bed. This anatomical and physiological targeting achieves a high tumor-to-normal-tissue uptake ratio, reported to be as high as 20:1.[9] This preferential deposition allows for the delivery of ablative radiation doses, often in the range of 50 to 150 Gray (Gy) or higher, directly to the tumor—doses that would be impossible to deliver safely with conventional external beam radiation, which is limited by the liver's low tolerance of approximately 30 Gy.[1]

Section 2: Commercial Formulations and Comparative Analysis

The clinical application of Y-90 radioembolization is facilitated through two principal types of commercially available microspheres: glass-based and resin-based. These platforms, while both utilizing Y-90, possess fundamental differences in their composition, physical properties, and dosimetric characteristics. These differences are not trivial; they represent distinct therapeutic tools with unique clinical profiles, and the choice between them is a critical aspect of treatment planning.

2.1 TheraSphere™: Y-90 Glass Microspheres

TheraSphere, manufactured by Boston Scientific, consists of non-biodegradable, insoluble glass microspheres.[3] In this formulation, the Yttrium-90 isotope is not merely coated on the surface but is an integral and inseparable constituent of the yttrium aluminum silicate glass matrix itself.[3] This is achieved through advanced manufacturing processes, such as the sol-gel method, which ensures the radioisotope is homogeneously distributed throughout each sphere.[23]

The defining physical characteristic of TheraSphere is its high specific activity. The microspheres have a mean diameter of 20-30 micrometers (µm), and each milligram of the product contains between 22,000 and 73,000 individual spheres.[3] This design results in a significantly higher concentration of radiation per microsphere compared to its resin-based counterpart.[23] Consequently, a full therapeutic radiation dose can be delivered with a relatively small number of particles. This low particle load minimizes the embolic component of the therapy; the primary mechanism of action is almost purely radiotherapeutic, focusing on delivering an ablative dose of radiation rather than physically occluding the vasculature.[1] This characteristic is often described as maximizing the "radiation per microsphere" to achieve potent tumor destruction with minimal ischemic effect.[23]

2.2 SIR-Spheres®: Y-90 Resin Microspheres

SIR-Spheres, manufactured by Sirtex Medical, are composed of a biocompatible resin based on a sulfonated divinyl benzene-styrene copolymer.[4] In this platform, the Yttrium-90 is impregnated or adsorbed onto the surface of the pre-formed resin beads.[26]

SIR-Spheres have a slightly larger and more variable diameter, typically ranging from 20 to 60 µm, with a stated average of 32±10 µm.[4] Their specific density is engineered to be between 1.125 and 1.6 g/ml, which is comparable to that of red blood cells.[4] This property is designed to facilitate their transport within the bloodstream, allowing them to travel deeply into the distal microvasculature of the tumor. Due to a lower activity per sphere, a therapeutic dose of SIR-Spheres requires a vastly greater number of particles. A standard 3 Gigabecquerel (GBq) dose, for example, contains approximately 44 million microspheres.[4] This high particle load results in a more pronounced embolic effect in addition to the radiotherapeutic action, creating a dual mechanism of tumor destruction through both radiation and ischemia.[1]

2.3 Head-to-Head Comparison and Clinical Selection Criteria

The fundamental distinction between the glass and resin platforms—low particle load with high activity per sphere versus high particle load with low activity per sphere—drives clinical decision-making. TheraSphere is a highly focused radiation delivery system, whereas SIR-Spheres offers a combined radio-embolic effect. This difference is not a matter of superiority but of selecting the appropriate tool for a specific clinical scenario. For instance, in cases where the goal is a purely ablative radiation dose with minimal disruption to blood flow (a technique known as radiation segmentectomy), the low particle load of TheraSphere may be preferred. Conversely, for a large, hypervascular tumor, the additional ischemic effect provided by the higher number of SIR-Spheres particles might be considered beneficial. The choice is therefore a strategic one, made by the multidisciplinary treatment team based on tumor characteristics, patient anatomy, and the overall therapeutic goal.

Table 1: Comparative Profile of TheraSphere™ and SIR-Spheres®

Attribute	TheraSphere™ (Glass Microspheres)	SIR-Spheres® (Resin Microspheres)
Core Material	Glass (Yttrium Aluminum Silicate) 3	Resin (Sulfonated Divinyl Benzene-Styrene Copolymer) 4
Isotope Integration	Integral to glass matrix 3	Adsorbed/Impregnated onto resin surface 26
Manufacturer	Boston Scientific Corporation 21	Sirtex Medical Pty Ltd 4
Microsphere Diameter	20–30 µm 3	20–60 µm (average 32±10 µm) 4
Specific Gravity	Not a primary design feature	~1.1–1.6 g/ml (comparable to red blood cells) 4
Activity per Sphere	High 23	Low
Approx. Spheres per Dose	~1.2–8.1 million (dose dependent)	~40–80 million 4
Primary Mechanism	Primarily Radiation 1	Radiation + Embolization 1
Key Pivotal HCC Trial	LEGACY 28	DOORwaY90 30

Section 3: Clinical Applications in Hepatic Malignancies

Yttrium-90 radioembolization has secured a vital role in the management of both primary and metastatic liver cancers. Its application has evolved significantly over time, moving from a primarily palliative option for end-stage disease to a strategic tool used across the treatment continuum, including as a neoadjuvant therapy to enable potentially curative interventions.

3.1 Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma, the most common type of primary liver cancer, is a principal indication for Y-90 radioembolization.

• Role in Unresectable HCC (uHCC): For the large proportion of patients who present with HCC that is unresectable due to tumor size, location, multifocality, or underlying liver dysfunction, Y-90 radioembolization serves as a standard-of-care locoregional therapy.[1] It is particularly effective for patients with large or numerous tumors where other ablative techniques are not feasible.[16] Clinical evidence demonstrates that the therapy can significantly prolong the time to disease progression and is generally well-tolerated, with a more favorable side-effect profile than systemic therapies like sorafenib.[1] A critical application is in patients with portal vein tumor thrombosis (PVTT), a frequent complication of advanced HCC that carries a grim prognosis. For these patients, Y-90 is often considered a superior and safer option compared to transarterial chemoembolization (TACE), which carries a higher risk of ischemic liver failure in the setting of compromised portal flow.[1]
• Neoadjuvant and Bridging Therapy: Perhaps the most impactful evolution in the use of Y-90 has been its integration into curative-intent pathways. This strategic shift has transformed the treatment landscape for patients with initially unresectable disease. Y-90 is now frequently employed as a neoadjuvant therapy to "downstage" tumors—that is, to shrink them sufficiently to meet the strict criteria for surgical resection or liver transplantation.[16] This application can successfully convert a patient's prognosis from palliative to potentially curative. In a related role as a "bridge-to-transplant," Y-90 provides durable local tumor control for patients on the lengthy transplant waiting list, preventing disease progression that would otherwise render them ineligible for the life-saving procedure.[31] Furthermore, when a large portion of the liver must be resected, a technique known as "radiation lobectomy" can be performed. By treating one lobe of the liver with Y-90, the therapy simultaneously destroys the tumor and induces atrophy in the treated lobe, which in turn stimulates compensatory hypertrophy (growth) of the contralateral, untreated future liver remnant (FLR). This increases the volume of the FLR, making a subsequent major hepatectomy significantly safer.[19]

3.2 Metastatic Liver Tumors

Y-90 radioembolization is also a valuable treatment for a variety of cancers that have metastasized to the liver, especially when the liver is the dominant or sole site of disease.[8]

• Metastatic Colorectal Cancer (mCRC): The liver is a common site of metastasis for colorectal cancer, and this is a key approved indication for Y-90 therapy. It is most often used in patients whose liver metastases are unresectable and have become refractory to multiple lines of systemic chemotherapy.[4]
• Other Metastases: The application of Y-90 extends to liver metastases originating from other primary sites, including neuroendocrine tumors (NETs), cholangiocarcinoma (bile duct cancer), melanoma, and breast cancer.[4] In these settings, it provides an effective means of locoregional disease control, can alleviate symptoms, and improve quality of life.

3.3 Summary of Clinical Trial Landscape

The clinical use of Y-90 is supported by a large and growing body of evidence from clinical trials.

• Overview of Trial Activity: The clinical trial landscape for Y-90 is dynamic. Currently recruiting trials are focused on investigating its use in combination with modern systemic agents, particularly immune checkpoint inhibitors like atezolizumab, bevacizumab, and cemiplimab, for both HCC and metastatic disease.[38] This focus reflects the broader shift in oncology toward combining locoregional and systemic treatments to achieve synergistic effects. Completed and terminated trials have explored Y-90 both as a monotherapy and in combination with older targeted agents like the tyrosine kinase inhibitor sorafenib.[40] The existence of active but non-recruiting Phase 3 trials for inoperable HCC indicates a mature evidence base in this core indication.[42]
• Analysis of Pivotal and Landmark Studies:
• LEGACY (TheraSphere): This prospective, single-arm study was pivotal in securing the full FDA approval for TheraSphere in the treatment of unresectable HCC. The trial demonstrated impressive efficacy, with a high objective response rate of 72.2% and a durable response in 76.1% of patients at six months. These results were instrumental in establishing TheraSphere as a standard treatment option for this patient population.[21]
• DOORwaY90 (SIR-Spheres): This prospective, multicenter trial provided the key evidence for the FDA approval of SIR-Spheres for unresectable HCC. The study reported outstanding local tumor control, with a best overall response rate of 98.5% and a 100% local disease control rate among evaluable patients, confirming its high efficacy.[30]
• SARAH and SIRveNIB: These two large, randomized controlled trials from the late 2010s compared Y-90 radioembolization (using SIR-Spheres) against the then-standard oral systemic therapy, sorafenib, in patients with advanced HCC.[31] Both trials failed to meet their primary endpoint of demonstrating superior overall survival for the Y-90 arm. While initially viewed as a setback, these trials provided invaluable lessons. Patients in the Y-90 arms reported significantly better quality of life and fewer treatment-related side effects than those on sorafenib.[31] More importantly, subsequent analyses revealed that the "failure" was not one of the technology itself, but of the treatment paradigm. Many patients in the trials did not receive a sufficiently high radiation dose to their tumors to be truly therapeutic. This realization highlighted the critical flaw in a "one-size-fits-all" dosing approach and became a major catalyst for the field to move toward more sophisticated, personalized dosimetry models to optimize treatment for each individual patient. The subsequent DOSISPHERE-01 trial later proved that when personalized dosimetry is used to achieve a high tumor-absorbed dose, Y-90 does indeed lead to superior outcomes, validating the lessons learned from SARAH and SIRveNIB.[31]

Section 4: The Radioembolization Procedure: From Patient Selection to Follow-Up

The successful administration of Y-90 radioembolization is a complex, multidisciplinary endeavor that extends far beyond the simple injection of microspheres. It is a therapy defined by meticulous planning and a focus on risk mitigation. The clinical workflow involves a multi-step process, beginning with rigorous patient selection and detailed pre-treatment assessment, followed by the therapeutic procedure itself, and concluding with post-treatment care and monitoring.

4.1 Patient Evaluation and Pre-Treatment Planning

• Inclusion and Exclusion Criteria: Careful patient selection is paramount to ensuring both safety and efficacy. Ideal candidates are those with primary or metastatic tumors confined to or dominant in the liver, who are not candidates for curative surgery.[8] Essential inclusion criteria include well-preserved liver function, typically defined as Child-Pugh Class A or well-compensated Class B, and a good overall performance status (e.g., Eastern Cooperative Oncology Group [ECOG] status of 0-2).[32] Absolute contraindications are designed to prevent severe complications and include pregnancy, severe pulmonary insufficiency, uncorrectable hepatoenteric arterial anatomy, and an excessive tumor burden (often defined as >70% of liver volume).[6]
• The Mapping Angiogram (Phase 1): The cornerstone of procedural safety is the preliminary mapping angiogram, performed by an interventional radiologist several days to weeks before the planned Y-90 infusion.[16] This diagnostic procedure is as critical as the therapy itself. A catheter is introduced, usually via an artery in the groin or wrist, and navigated under X-ray (fluoroscopic) guidance into the hepatic arterial system.[16] This mapping phase has three primary objectives:

1. Define Vascular Anatomy: To create a detailed map of the arteries supplying the liver and, specifically, the tumor(s).[16]
2. Prevent Gastrointestinal Toxicity: To identify any arteries that branch off the hepatic circulation and supply non-target organs like the stomach, pancreas, or bowel. If such vessels are found, they are proactively occluded ("coil embolized") with tiny platinum coils. This crucial step prevents the inadvertent flow of radioactive microspheres to these organs, which would otherwise cause painful and severe gastrointestinal ulceration.[11]
3. Quantify Lung Shunt Fraction: A diagnostic dose of Technetium-99m macroaggregated albumin ($^{99m}$Tc-MAA) is injected into the target artery. These particles are similar in size to the Y-90 microspheres and thus mimic their biodistribution.[11] A subsequent nuclear medicine scan is performed to measure the percentage of these particles that bypass the liver's capillary beds and travel to the lungs—the "lung shunt fraction".[11] If the shunt is too high (typically >20%), resulting in a calculated radiation dose to the lungs that would exceed 30 Gy, the treatment is deemed unsafe and is cancelled. This step is the primary method for preventing potentially fatal radiation pneumonitis.[6]

4.2 Therapeutic Administration (Phase 2)

• Catheterization and Infusion: The therapeutic procedure, typically performed as an outpatient service, takes place approximately one to two weeks after the mapping angiogram.[16] The process largely replicates the mapping phase. Under local anesthesia and conscious sedation, the interventional radiologist re-accesses the hepatic artery and carefully positions the microcatheter in the previously identified target vessel(s).[18] The prescribed, patient-specific dose of Y-90 microspheres is then slowly and carefully infused over several minutes.[11] The arterial blood flow carries the microspheres into the tumor's distal vasculature, where they become permanently entrapped, beginning their process of emitting localized radiation.[8]
• Post-Infusion Imaging: Immediately after the infusion is complete, the patient undergoes imaging to verify the final distribution of the radioactive microspheres.[2] This is essential to confirm successful targeting of the tumor and to rule out any significant non-target deposition. The imaging is most commonly performed with SPECT/CT, which detects the Bremsstrahlung radiation, or with the higher-resolution modality of PET/CT, which can detect the small number of positrons generated during Y-90 decay.[2]

4.3 Safety, Tolerability, and Management of Adverse Events

• Common Side Effects (Post-Embolization Syndrome): The majority of patients will experience a predictable and manageable set of symptoms known as post-embolization syndrome. This syndrome, which is an inflammatory response to the tumor necrosis and embolization, typically manifests within a few days of the procedure and can last for one to two weeks. Symptoms include fatigue (the most common), low-grade fever, nausea, vomiting, and abdominal pain or discomfort.[1] These are typically managed with supportive care, including antiemetics and analgesics.
• Significant Risks and Complications: While the procedure is generally safe when performed by experienced teams, serious complications can occur, primarily due to the unintended delivery of radiation to non-target tissues.
• Radiation Safety Precautions: Although the beta radiation is contained within the body, patients do emit a low level of external Bremsstrahlung radiation. As a precaution, for the first week following treatment, patients are typically advised to follow simple radiation safety measures. These include avoiding sleeping in the same bed as a partner and limiting prolonged (>12 hours per day), close (<1 foot) contact with other people, especially children and pregnant women.[19]

Table 2: Summary of Key Adverse Events and Management Strategies

Adverse Event	Typical Onset	Mechanism / Cause	Prevention & Management
Post-Embolization Syndrome (Fatigue, Nausea, Pain, Fever)	Days to 2 weeks	Inflammatory response to tumor necrosis and embolization 7	Management: Prophylactic and symptomatic relief with antiemetics, analgesics, and antipyretics.19
Gastrointestinal Ulceration	Weeks to months	Non-target embolization of microspheres to arteries supplying the stomach or duodenum 1	Prevention: Meticulous pre-treatment mapping and prophylactic coil embolization of hepatoenteric arteries.16 Management: Proton pump inhibitors, sucralfate.
Radiation Pneumonitis	Weeks to months	Excessive shunting of microspheres from the liver to the lungs, leading to high radiation dose 11	Prevention: Mandatory pre-treatment $^{99m}$Tc-MAA lung shunt calculation. Dose is reduced or procedure is cancelled if calculated lung dose exceeds safety thresholds (~30 Gy).6
Radioembolization-Induced Liver Disease (REILD)	1-3 months	Excessive radiation dose delivered to the normal, non-tumorous liver parenchyma, leading to sinusoidal injury 27	Prevention: Careful patient selection (good baseline liver function) and sophisticated, personalized dosimetry to limit dose to normal liver. Management: Primarily supportive care.

Section 5: Regulatory and Global Market Landscape

The availability and approved uses of Y-90 radioembolization technologies are governed by national and regional regulatory bodies. The regulatory pathways for TheraSphere and SIR-Spheres have evolved over time, reflecting a broader trend toward requiring more rigorous, indication-specific clinical data for high-risk medical devices.

5.1 United States Food and Drug Administration (FDA)

• TheraSphere™: For many years, TheraSphere was available in the U.S. under a Humanitarian Device Exemption (HDE), a regulatory pathway for devices intended to treat rare diseases that has a different evidence standard than full approval and limits the number of patients that can be treated annually.[3] This changed on March 18, 2021, when Boston Scientific received full Premarket Approval (PMA) from the FDA for TheraSphere for the treatment of patients with unresectable HCC.[28] This landmark approval was based on the strength of the data from the LEGACY study. The specific indication is for the local tumor control of solitary tumors (1-8 cm in diameter) in patients with unresectable HCC, Child-Pugh Score A cirrhosis, well-compensated liver function, and no macrovascular invasion.[45]
• SIR-Spheres®: Sirtex Medical received its initial FDA PMA for SIR-Spheres on March 5, 2002 (PMA number P990065).[12] The original indication was for the treatment of unresectable metastatic liver tumors from primary colorectal cancer (mCRC), intended for use with adjuvant intra-hepatic artery chemotherapy (IHAC) of Floxuridine (FUDR).[12] More recently, following the successful DOORwaY90 clinical trial, Sirtex received an expanded FDA approval on July 7, 2025 (note: future date from source material), for the treatment of unresectable HCC. This made SIR-Spheres the only radioembolization therapy in the U.S. with specific FDA approvals for both mCRC and HCC.[30]

5.2 European CE Mark Certification

The CE Mark indicates conformity with health and safety standards for products sold within the European Economic Area.

• TheraSphere™: The widespread global use of TheraSphere, including in over 70,000 patients, and its positive recommendation by the UK's National Institute for Health and Care Excellence (NICE) for treating HCC, implies a long-standing CE Mark approval, although specific dates are not detailed in the provided materials.[28]
• SIR-Spheres®: Sirtex has actively updated its European regulatory status. In September 2024, the company announced it had received certification for SIR-Spheres under the new, more stringent Medical Device Regulation (EU) 2017/745.[51] Subsequently, on September 8, 2025 (note: future date from source material), Sirtex announced it had received an expanded CE Mark approval. This expansion broadened the indication to cover the treatment of both primary and secondary liver metastases, significantly increasing the eligible patient population within Europe.[51]

5.3 Australian Therapeutic Goods Administration (TGA)

• TheraSphere™: The device is registered on the Australian Register of Therapeutic Goods (ARTG ID 512508) under the sponsorship of Boston Scientific Pty Ltd. It is classified as a Class III medical device, with a listed entry date of September 22, 2025 (note: future date from source material).[22]
• SIR-Spheres®: The device is registered on the ARTG (ARTG ID 149332) under the sponsorship of its manufacturer, Sirtex Medical Pty Ltd, with an original entry date of January 21, 2008.[25] It is classified as an Active Implantable Medical Device (AIMD). The TGA-approved indication is notably broad, covering "the treatment of malignant liver tumours of primary or secondary origin that are not suitable for resection or ablation".[53]

5.4 Summary of Global Regulatory Approvals

The differing regulatory histories and indications highlight the importance of consulting local approvals for clinical use. The trend is clearly toward requiring robust, prospective clinical trial data for each specific cancer type, moving away from broader or exemption-based approvals.

Table 3: Global Regulatory Approvals and Key Indications for Y-90 Microspheres

Product	FDA (United States)	CE Mark (Europe)	TGA (Australia)
TheraSphere™	Unresectable HCC (solitary tumors 1-8cm, Child-Pugh A) 28	Approved for use in HCC (inferred from NICE recommendation) 28	Registered as a Class III medical device 22
SIR-Spheres®	- Unresectable mCRC (with FUDR)- Unresectable HCC 30	Primary and secondary liver metastases (expanded indication) 51	Malignant liver tumors (primary or secondary) unsuitable for resection or ablation 53

Section 6: Comparative Efficacy and Future Perspectives

Yttrium-90 radioembolization does not exist in a therapeutic vacuum. Its role in modern oncology is defined by its relationship to other available treatments, including other locoregional therapies, systemic agents, and surgery. The future of the modality lies not in replacing these other treatments, but in its intelligent and synergistic integration into multimodal care pathways.

6.1 Y-90 Radioembolization vs. Alternative Therapies

• vs. Transarterial Chemoembolization (TACE): TACE is another established catheter-based therapy for HCC. It differs from TARE by using larger embolic particles (100-300 µm) to deliver a payload of chemotherapy and induce a more profound ischemic effect.[1] While clinical outcomes are often comparable for patients with intermediate-stage HCC, TARE is generally better tolerated, with a less severe post-embolization syndrome and an absence of chemotherapy-related systemic side effects.[1] Critically, TARE is considered the safer and more effective option for patients with portal vein tumor thrombosis, where the profound embolization of TACE could precipitate liver failure.[1]
• vs. Systemic Therapies: The landmark SARAH and SIRveNIB trials established that TARE, while not superior in overall survival, offered a significantly better quality of life and tolerability compared to the oral tyrosine kinase inhibitor sorafenib for advanced HCC.[31] The current standard of care for advanced HCC has since shifted to immunotherapy-based combinations (e.g., atezolizumab plus bevacizumab). The role of TARE is therefore not to compete with these effective systemic agents, but to complement them. TARE offers potent locoregional control with a distinct toxicity profile, making it a valuable tool within a broader treatment strategy.
• vs. External Beam Radiation Therapy (EBRT): The primary advantage of TARE over conventional EBRT is its ability to deliver a much higher and more targeted dose of radiation. The healthy liver is highly sensitive to radiation, limiting the dose from whole-liver EBRT to a sub-therapeutic level of around 30 Gy.[1] TARE overcomes this limitation by concentrating the radiation within the tumor, allowing for doses of 100 Gy or more to be delivered safely.[1] While modern EBRT techniques like Stereotactic Body Radiation Therapy (SBRT) can also deliver high doses, TARE may be better suited for treating multifocal or diffusely infiltrating tumors. Importantly, evidence suggests that prior treatment with TARE does not preclude the safe and effective use of EBRT later in the treatment course for well-selected patients.[55]
• vs. Surgical Resection: For patients with resectable liver tumors, surgical resection remains the gold standard with the highest chance of cure.[33] TARE is not a substitute for surgery but rather a powerful enabling technology. For patients with initially unresectable or borderline resectable disease, preoperative TARE has been shown to improve long-term oncological outcomes, including recurrence-free and cancer-specific survival, without increasing the risks of major surgery.[33] By inducing significant tumor necrosis and facilitating hypertrophy of the future liver remnant, TARE can transform an inoperable patient into a surgical candidate, fundamentally altering their prognosis.[33]

6.2 Emerging Trends and Future Directions

The field of Y-90 radioembolization is continuously evolving, driven by technological advancements and a deeper understanding of its biological effects.

• Combination Therapies: The most promising frontier for TARE is its combination with systemic therapies, particularly immunotherapy. There is a strong scientific rationale for this synergy. The localized, high-dose radiation delivered by Y-90 can induce immunogenic cell death, causing tumor cells to release antigens that can be recognized by the immune system. This process may effectively turn the irradiated tumor into an in situ, personalized cancer vaccine. This localized immune stimulation could enhance the effectiveness of systemic immune checkpoint inhibitors, potentially overcoming resistance and improving outcomes for patients.[31] Numerous clinical trials are actively investigating this hypothesis, exploring combinations of TARE with agents like atezolizumab and bevacizumab.[31]
• Advancements in Personalized Dosimetry: The lessons learned from early randomized trials have cemented the principle that personalized dosimetry is not optional, but essential for optimal outcomes.[31] The future of TARE will involve more sophisticated and integrated approaches to treatment planning. This includes the use of advanced imaging techniques (e.g., PET/CT, MRI) and complex software algorithms to more accurately predict the distribution of microspheres and calculate the absorbed radiation dose to both the tumor and the normal liver. The goal is to tailor the administered activity for each patient to maximize the tumoricidal dose while strictly adhering to safety constraints for healthy tissue.
• Expanded Roles and Indications: Research continues to push the boundaries of TARE's applications. There is growing interest in its use as a definitive, ablative therapy for patients with "oligometastatic" disease (a limited number of metastases), where it could be used in conjunction with other local treatments like surgery or thermal ablation with curative intent.[44] Its role as a neoadjuvant therapy to improve the safety and efficacy of surgery is also a rapidly expanding area of investigation and clinical practice, solidifying its position as a critical component of multidisciplinary cancer care.[33]

Section 7: Conclusion

Yttrium-90 is a radiopharmaceutical agent whose clinical utility is defined by a confluence of favorable isotopic properties and a highly targeted delivery mechanism. As a pure beta emitter with a short tissue penetration range and a moderate half-life, it is exceptionally suited for delivering localized, high-dose radiation in the form of brachytherapy. The TARE/SIRT procedure masterfully exploits the unique hypervascularity of hepatic tumors to preferentially deliver Y-90-loaded microspheres, achieving potent tumoricidal effects while sparing the majority of healthy liver tissue.

The clinical landscape is dominated by two distinct platforms, glass-based TheraSphere and resin-based SIR-Spheres, which offer different balances of radiotherapeutic and embolic effects, allowing for tailored treatment strategies. The regulatory approval of these devices across major global markets has been increasingly driven by robust, indication-specific clinical data from pivotal trials such as LEGACY and DOORwaY90, reflecting a maturation of the field.

Most significantly, the clinical role of Y-90 radioembolization has undergone a profound strategic evolution. It has transitioned from being primarily a palliative, end-of-line therapy to a versatile and proactive tool integrated across the treatment continuum. Its application as a neoadjuvant therapy to downstage tumors for resection or as a bridge-to-transplantation has created pathways to a potential cure for patients with previously unresectable disease. The future of Y-90 lies not in competition with other modalities, but in synergy. The ongoing exploration of its combination with systemic immunotherapies and the continuous refinement of personalized dosimetry promise to further enhance its efficacy and solidify its role as an indispensable component in the multidisciplinary management of primary and metastatic liver cancer.

Works cited

1. Radioembolization with Yttrium-90 microspheres for patients with ..., accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4570909/
2. Yttrium-90 - Wikipedia, accessed October 19, 2025, https://en.wikipedia.org/wiki/Yttrium-90
3. TheraSphere - Wikipedia, accessed October 19, 2025, https://en.wikipedia.org/wiki/TheraSphere
4. About SIR-Spheres - Sirtex, accessed October 19, 2025, https://www.sirtex.com/ap/products/sir-spheres-y-90-resin-microspheres/about-sir-spheres/
5. Yttrium-90 | Radiology Reference Article | Radiopaedia.org, accessed October 19, 2025, https://radiopaedia.org/articles/yttrium-90
6. Packa e Insert - accessdata.fda.gov, accessed October 19, 2025, https://www.accessdata.fda.gov/cdrh_docs/pdf/h980006c.pdf
7. What is the mechanism of Yttrium 90? - Patsnap Synapse, accessed October 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-yttrium-90
8. Yttrium-90 Radioembolization - UCSF Department of Surgery, accessed October 19, 2025, https://surgery.ucsf.edu/procedure/yttrium-90-radioembolization
9. Use of yttrium-90 radioembolization for patients with unresectable liver metastases: experience from a single center - Translational Cancer Research, accessed October 19, 2025, https://tcr.amegroups.org/article/view/6426/html
10. Y-90 radioembolization for liver cancer, accessed October 19, 2025, https://www.medparkhospital.com/en-US/disease-and-treatment/y-90-radioembolization-for-liver-cancer
11. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6095426/
12. Summary of Safety and Effectiveness Data - accessdata.fda.gov, accessed October 19, 2025, https://www.accessdata.fda.gov/cdrh_docs/pdf/p990065b.pdf
13. SIR-Spheres ® Y-90 Resin Microspheres - Sirtex, accessed October 19, 2025, https://www.sirtex.com/us/products/sir-spheres/sir-spheres-y-90-resin-microspheres/about-sir-spheres/
14. WO2017004088A1 - Yttrium-90 production system and method - Google Patents, accessed October 19, 2025, https://patents.google.com/patent/WO2017004088A1/en
15. Yttrium-90 | NRG PALLAS, accessed October 19, 2025, https://www.nrgpallas.com/medical-isotope-solutions/radioisotopes/yttrium-90
16. Y90 Radioembolization - MD Anderson Cancer Center, accessed October 19, 2025, https://www.mdanderson.org/treatment-options/y90-radioembolization.html
17. Radioembolization - Yttrium-90 Microsphere - Stanford Health Care, accessed October 19, 2025, https://stanfordhealthcare.org/medical-treatments/r/radioembolization.html
18. Understanding Yttrium 90 Radioembolization - UMass Memorial Health, accessed October 19, 2025, https://www.ummhealth.org/health-library/understanding-yttrium-90-radioembolization
19. Radioembolization (Y90) - Radiologyinfo.org, accessed October 19, 2025, https://www.radiologyinfo.org/en/info/radioembol
20. Selective Internal Radiation Therapy [SIRT]: SIR-Spheres® - InsideRadiology, accessed October 19, 2025, https://www.insideradiology.com.au/sirt/
21. Yttrium-90 TheraSphere Liver Cancer Therapy - Boston Scientific, accessed October 19, 2025, https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology/therasphere.html
22. Boston Scientific Pty Ltd - TheraSphere™ Yttrium-90 Glass Microspheres - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant (512508), accessed October 19, 2025, https://www.tga.gov.au/resources/artg/512508
23. TheraSphere™ Y-90 Glass Microspheres - Boston Scientific, accessed October 19, 2025, https://www.bostonscientific.com/us/en/healthcare-professionals/products/radioembolization/therasphere-y-90-glass-microspheres/fp00000390.html
24. A novel way to production yttrium glass microspheres for medical applications, accessed October 19, 2025, https://www.researchgate.net/publication/271663897_A_novel_way_to_production_yttrium_glass_microspheres_for_medical_applications
25. Sirtex Medical Pty Ltd - SIR-Spheres - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant (149332), accessed October 19, 2025, https://www.tga.gov.au/resources/artg/149332
26. SIR-Spheres - Wikipedia, accessed October 19, 2025, https://en.wikipedia.org/wiki/SIR-Spheres
27. SIR-Spheres ® Y-90 Resin Microspheres - Sirtex, accessed October 19, 2025, https://www.sirtex.com/us/patients/sir-spheres-y-90-resin-microspheres/
28. TheraSphere SIRT Received FDA Approval for Treatment of Unresectable HCC, accessed October 19, 2025, https://www.cancernetwork.com/view/therasphere-sirt-received-fda-approval-for-treatment-of-unresectable-hcc
29. FDA Clears Boston Scientific TheraSphere Y-90 Transcatheter Liver Embolization Microspheres - Diagnostic and Interventional Cardiology, accessed October 19, 2025, https://www.dicardiology.com/content/fda-clears-boston-scientific-therasphere-y-90-transcatheter-liver-embolization-microspheres
30. jesse.hansen@sirtex.com Sirtex Medical's SIR-Spheres® Y-90 Resin Microsphere, accessed October 19, 2025, https://www.sirtex.com/media/p1kjiw5m/sirtex-medical-announces-fda-approval-hcc-indication-us.pdf
31. Overview of Yttrium-90 radioembolization for advanced hepatocellular carcinoma: Current status and future perspectives - PubMed, accessed October 19, 2025, https://pubmed.ncbi.nlm.nih.gov/41024843/
32. A Systematic Review on the Safety and Effectiveness of yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis - PMC - PubMed Central, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5051218/
33. Impact of Preoperative Yttrium-90 Transarterial Radioembolization on Patients Undergoing Right or Extended Right Hepatectomy for Hepatocellular Carcinoma - MDPI, accessed October 19, 2025, https://www.mdpi.com/2072-6694/17/15/2556
34. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience - PMC - PubMed Central, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9913597/
35. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma | Request PDF - ResearchGate, accessed October 19, 2025, https://www.researchgate.net/publication/349677258_A_comparative_study_of_portal_vein_embolization_versus_radiation_lobectomy_with_Yttrium-90_micropheres_in_preparation_for_liver_resection_for_initially_unresectable_hepatocellular_carcinoma
36. Yttrium-90 | Y | CID 104760 - PubChem, accessed October 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Yttrium-90
37. P990065 - Premarket Approval (PMA) - FDA, accessed October 19, 2025, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p990065
38. Yttrium Y-90 Recruiting Phase 2 Trials for Hepatic Metastases Treatment | DrugBank Online, accessed October 19, 2025, https://go.drugbank.com/drugs/DB13076/clinical_trials?conditions=DBCOND0032606&phase=2&purpose=treatment&status=recruiting
39. Hepatic Carcinoma Recruiting Phase 1 / 2 Trials for Yttrium Y-90 (DB13076) - DrugBank, accessed October 19, 2025, https://go.drugbank.com/indications/DBCOND0043539/clinical_trials/DB13076?phase=1%2C2&status=recruiting
40. Yttrium Y-90 Terminated Phase 0 Trials for Hepatocellular Carcinoma Treatment - DrugBank, accessed October 19, 2025, https://go.drugbank.com/drugs/DB13076/clinical_trials?conditions=DBCOND0030090&phase=0&purpose=treatment&status=terminated
41. Yttrium Y-90 Completed Phase 1 Trials for Hepatocellular Carcinoma Treatment - DrugBank, accessed October 19, 2025, https://go.drugbank.com/drugs/DB13076/clinical_trials?conditions=DBCOND0030090&phase=1&purpose=treatment&status=completed
42. Inoperable Hepatocellular Carcinoma Active Not Recruiting Phase 3 Trials for Yttrium Y-90 (DB13076) - DrugBank, accessed October 19, 2025, https://go.drugbank.com/indications/DBCOND0043331/clinical_trials/DB13076?phase=3&status=active_not_recruiting
43. FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable HCC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways, accessed October 19, 2025, https://www.targetedonc.com/view/fda-approves-therasphere-y-90-glass-microspheres-for-unresectable-hcc
44. Yttrium 90 Therapy: Is the Future Surgical? - PMC, accessed October 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7649158/
45. P200029 - TheraSphere Instructions for Use - accessdata.fda.gov, accessed October 19, 2025, https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029C.pdf
46. Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma - NCI - National Cancer Institute, accessed October 19, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-09476
47. Therasphere Y-90 Microspheres indications, safety, and warnings - Boston Scientific, accessed October 19, 2025, https://www.bostonscientific.com/us/en/healthcare-professionals/products/radioembolization/therasphere-y90-glass-microspheres/fp00000390/therasphere-y90-microspheres-indications-safety-warnings.html
48. Radioembolization (Y90) - Interventional Radiology - UCLA Health, accessed October 19, 2025, https://www.uclahealth.org/medical-services/radiology/interventional-radiology/treatments-procedures/radioembolization-y90
49. Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC | Nasdaq, accessed October 19, 2025, https://www.nasdaq.com/articles/boston-scientifics-bsx-therasphere-approved-by-fda-for-hcc-2021-03-22
50. Approved Indication - Sirtex, accessed October 19, 2025, https://www.sirtex.com/us/products/sir-spheres/sir-spheres-y-90-resin-microspheres/approved-indication/
51. Press Releases - Sirtex, accessed October 19, 2025, https://www.sirtex.com/eu/news/press-releases/
52. Sirtex receives expanded CE mark approval for SIR-Spheres Y90 resin microspheres, accessed October 19, 2025, https://interventionalnews.com/sirtex-receives-expanded-ce-mark-approval-for-sir-spheres-y-90-resin-microspheres/
53. 1468 Primary Liver - Medical Services Advisory Committee, accessed October 19, 2025, https://www.msac.gov.au/sites/default/files/2024-11/application_form_-_sir_spheres_-_primary_liver_-_jan17.pdf
54. Chemoembolization and Radioembolization for Difficult Liver Tumors; Choice May Depend on Blood Flow - Medical Update, accessed October 19, 2025, https://medicalupdate.pennstatehealth.org/cardiology/chemoembolization-and-radioembolization-for-difficult-liver-tumors-choice-may-depend-on-blood-flow/
55. Hepatotoxicity following external radiotherapy in patients with hepatocellular carcinoma treated with or without prior yttrium-90 radioembolization. | Journal of Clinical Oncology - ASCO Publications, accessed October 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.564